Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.24

Mkt cap

15M

Volume

80K

High

1.27

P/E Ratio

-0.60

52-wk high

7.33

Low

1.21

Div yield

N/A

52-wk low

1.10

In Tuesday's intraday session, several health care stocks experienced significant movements. Akili, Cyclacel Pharmaceuticals, Eliem Therapeutics, GeneDx Hldgs, Dare Bioscience, and Lucid Diagnostics were among the gainers, with Akili leading at a 70.1% increase. On the downside, NRX Pharmaceuticals, Innovative Eyewear, Vaxxinity, Barinthus Biotherapeutics, Annovis Bio, and OpGen saw notable declines, with NRX Pharmaceuticals dropping by 23.9%.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 4:31 pm

NRx Pharmaceuticals shares dropped following the announcement of results from its Phase 2b/3 trial of NRX-101 vs. Lurasidone, indicating potentially disappointing outcomes or market reactions.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 1:19 pm

NRx Pharmaceuticals announced that both NRX-101 and lurasidone, a standard treatment for Bipolar Depression, showed a roughly 50% reduction in depression symptoms. This positions NRX-101 as a potentially significant treatment option alongside established medications.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:38 pm

NRX Pharmaceuticals announced the pricing of a $2 million underwritten public offering, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 7:10 pm

U.S. stocks traded lower with the NASDAQ down 0.5%. D.R. Horton reported better-than-expected Q2 results. AGBA surged 130% after a merger agreement with Triller. 23andMe rose 41% on private take-over considerations. TH International reported increased Q4 results. SuperCom, Lithium Americas, and NRx Pharmaceuticals saw significant drops after financial announcements.

Portfolio Pulse from Avi Kapoor

April 18, 2024 | 6:54 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Bio-Path Holdings, Aileron Therapeutics, 23andMe Holding, SINTX Techs, iSpecimen, and Benitec Biopharma were among the gainers, with increases ranging from 25.62% to 67.1%. On the downside, SeaStar Medical Holding, Aptorum Group, NRX Pharmaceuticals, Genetic Technologies, Ontrak, and INVO Bioscience saw declines between 20.34% and 27.0%. These movements were influenced by recent earnings reports and market dynamics.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 4:31 pm

U.S. stocks traded higher with the S&P 500, Dow, and NASDAQ all seeing gains. D.R. Horton reported better-than-expected Q2 results. AGBA Group announced a merger with Triller, causing its shares to surge. 23andMe and Bio-Path Holdings also saw significant stock increases, while SuperCom, Lithium Americas, and NRx Pharmaceuticals experienced declines. Oil prices edged lower, while gold, silver, and copper traded higher. European and Asian markets mostly rose, with economic data indicating mixed signals.

Portfolio Pulse from Avi Kapoor

April 18, 2024 | 4:08 pm

Las Vegas Sands Corp. (LVS) shares fell by around 7% despite reporting better-than-expected Q1 results, with earnings of 75 cents per share and sales of $2.96 billion. Other stocks also showed significant movement, with AGBA Group Holding Limited (AGBA) and Tian Ruixiang Holdings Ltd (TIRX) among the top gainers, while iLearningEngines Holdings, Inc. (AILE) and SuperCom Ltd (SPCB) led the losers.

Portfolio Pulse from Avi Kapoor

April 18, 2024 | 3:32 pm

U.S. stocks showed mixed performance with the Dow Jones gaining over 100 points, while NASDAQ fell slightly. D.R. Horton reported better-than-expected Q2 earnings, with shares of AGBA, TIRX, and BPTH surging on positive news. Conversely, AILE, LAC, and NRXP shares fell due to various challenges. The article also highlights sector performances, commodity updates, and global market trends.

Portfolio Pulse from Avi Kapoor

April 18, 2024 | 2:04 pm

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has regained compliance with Nasdaq's bid price requirement, ensuring its continued listing. The company anticipates reaching four key milestones, including data releases from trials in Suicidal Bipolar Depression and Chronic Pain, an NDA filing for IV Ketamine, and a distribution of HOPE Therapeutics shares to shareholders. Recent advancements in ketamine formulations and potential treatments for UTI/pyelonephritis could significantly enhance shareholder value.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 12:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.